Julie Khlevner, MD, AGAF

An expert outlines communication and shared decision-making strategies that support adherence and trust, and describes emerging patient-centered outcomes that are reshaping future care paradigms in pediatric functional constipation and IBS-C.

Explore the heterogeneity of pediatric functional constipation and IBS-C, the limitations of one-size-fits-all algorithms, and the importance of integrating dietary, behavioral, and psychosocial interventions alongside pharmacologic therapy.

An expert reviews the pediatric IBS-C label expansion for linaclotide, discusses how it addresses historical evidence gaps, and outlines practical considerations for patient selection, counseling, and monitoring.

An expert underscores the importance of early expectation setting around chronicity, symptom variability, and realistic treatment goals for children with functional constipation or IBS-C.

Learn how Rome V criteria, predominant symptom drivers, and a positive diagnostic framework help clinicians distinguish functional constipation from pediatric IBS-C and move away from a diagnosis-of-exclusion mindset.

Julie Khlevner, MD, discusses the clinical impact of FDA approval of linaclotide for children aged 2 to 5 years with functional constipation.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.